SHANGHAI — On April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (“OBiO” or “the Company”), a leading gene and cell therapy CDMO in China, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in the China (Shanghai) Pilot Free Trade Zone, Lin-Gang Special Area, with 29 production lines and 828,000+ square feet in area, which was one of the biggest super factories for gene therapy in the world. [Read more…]
ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Cord Blood-Derived NK Cell Immunotherapies
Biotech company taps into human diversity for next-generation NK cell therapies
SAN FRANCISCO–ImmuneBridge, a biotechnology company using nature’s innate intelligence to fight cancer, today announced the close of an oversubscribed $12 million seed financing co-led by global investors Insight Partners and M Ventures, the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. One Way Ventures and Gaingels also participated. Cheryl Zimberlin, Investment Director at M Ventures, and Dylan Morris, Managing Director at Insight Partners have joined ImmuneBridge’s Board of Directors. [Read more…]
Stem Cell Infusion: What to Expect
In recent years, stem cell infusion has become a breakthrough technology. There have been multiple medical leaders citing regenerative medicine as the way of the future. Stem cells obviate our need to patch up the body or create stopgap measures for systems that don’t work. They instead promise to replace organs and tissues that no longer function, essentially rebuilding the body from the inside out. Naturally, science has not progressed to the point of spreading this technology across the globe. However, the growing availability and efficacy of stem cell infusion indicate this isn’t far off, either. [Read more…]
Center for Breakthrough Medicines, Nucleus Biologics, and Stoic Bio Announce Strategic Collaboration for Steady Supply of Quality Controlled Cell Culture Media to Expedite Development of Cell and Gene Therapies
March 7, 2023, SAN DIEGO, CA — In a joint effort to accelerate high-quality therapies to market, Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media solutions for the cell and gene therapy industry, and Stoic Bio, a provider of sustainable technology for cell media manufacturing, have announced plans for a supply agreement with the Center for Breakthrough Medicines (CBM), a leading contract development and manufacturing organization (CDMO), whose mission is to save lives by accelerating the development and manufacture of advanced therapies. This agreement makes Nucleus Biologics the preferred supplier of cell culture media and other critical biological solutions for CBM; thus, ensuring a steady, consistent supply of this critical material with tighter quality control measures. [Read more…]
Interview with Patrick Lucy, President and CEO of Lykan Bioscience
This is an interview with Patrick Lucy, President and CEO of Lykan Bioscience. Lykan is an innovative cell therapy-focused contract development and manufacturing organization (CDMO) headquartered in Hopkinton, MA. In this interview, we discuss the vision of Lykan Bioscience, its innovative and agile approach to CDMO services, and the company’s future goals. Enjoy! [Read more…]
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 47
- Next Page »